These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33569738)

  • 1. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
    Li S; Hu H; Ding D; Zhu Y; Huang J
    Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.
    Trouiller JB; Macabeo B; Poll A; Howard D; Buckland A; Sivignon M; Clay E; Malka D; Samalin E; Toumi M; Laramée P
    BMJ Open; 2022 Nov; 12(11):e063700. PubMed ID: 36410812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
    Kopetz S; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Belani A; Zhang X; Tabernero J
    ESMO Open; 2022 Jun; 7(3):100477. PubMed ID: 35653981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.
    Gallois C; Bergen ES; Auclin É; Pernot S; Higué J; Trouilloud I; Touchefeu Y; Turpin A; Mazard T; Sartore-Bianchi A; Prenen H; Alberti A; Pilla L; Cuissy S; Wookey V; Perret A; Melchior C; Artru P; Dubreuil O; Drouillard A; Doat S; Lavolé J; Basile D; Perkins G; Jary M; Stintzing S; Ros J; Tougeron D; Taieb J
    ESMO Open; 2024 Sep; 9(9):103696. PubMed ID: 39255538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encorafenib, Binimetinib, and Cetuximab in
    Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
    N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
    Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J
    J Clin Oncol; 2019 Jun; 37(17):1460-1469. PubMed ID: 30892987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
    Patel KK; Stein S; Lacy J; O'Hara M; Huntington SF
    JAMA Netw Open; 2021 Jan; 4(1):e2033441. PubMed ID: 33433598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
    Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
    ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
    Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
    J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer.
    Giuliani J; Mantoan B; Bonetti A
    J Oncol Pharm Pract; 2022 Jan; 28(1):199-202. PubMed ID: 34581610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF
    Kotani D; Takashima A; Kato T; Satoh T; Masuishi T; Komatsu Y; Shiozawa M; Esaki T; Izawa N; Takeuchi S; Bando H; Iwasa S; Hasegawa H; Yamaguchi T; Taniguchi H; Ushida Y; Oizaki T; Inoue C; Yoshino T
    Clin Colorectal Cancer; 2024 Jun; 23(2):174-182.e6. PubMed ID: 38553360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
    Shahjehan F; Kamatham S; Chandrasekharan C; Kasi PM
    Drugs Today (Barc); 2019 Nov; 55(11):683-693. PubMed ID: 31840683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.
    Kotani D; Bando H; Taniguchi H; Masuishi T; Komatsu Y; Yamaguchi K; Nakajima T; Satoh T; Nishina T; Esaki T; Nomura S; Takahashi K; Iida S; Matsuda S; Motonaga S; Fuse N; Sato A; Fujii S; Ohtsu A; Ebi H; Yoshino T
    ESMO Open; 2020; 5(1):e000624. PubMed ID: 33551068
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Imai T; Shoji H; Hirano H; Matsuguma K; Awatsu T; Hirose T; Okita N; Takashima A; Kato K
    CNS Oncol; 2024 Jun; 13(1):2347824. PubMed ID: 38869444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated
    Van Cutsem E; Taieb J; Yaeger R; Yoshino T; Grothey A; Maiello E; Elez E; Dekervel J; Ross P; Ruiz-Casado A; Graham J; Kato T; Ruffinelli JC; André T; Carrière Roussel E; Klauck I; Groc M; Vedovato JC; Tabernero J
    J Clin Oncol; 2023 May; 41(14):2628-2637. PubMed ID: 36763936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III
    Boku S; Satake H; Ohta T; Mitani S; Kawakami K; Suzuki Y; Matsumoto T; Terazawa T; Yamazaki E; Hasegawa H; Ikoma T; Uemura M; Yamaguchi T; Naito A; Ishizuka Y; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Tsujinaka T; Kato T; Satoh T; Kagawa Y
    Future Oncol; 2022 Dec; 18(38):4153-4160. PubMed ID: 36475784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
    Al-Salama ZT
    Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BEETS (JACCRO CC-18) trial: an observational and translational study of
    Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y
    Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF
    Ji J; Wang C; Fakih M
    Clin Colorectal Cancer; 2022 Sep; 21(3):267-271. PubMed ID: 35039233
    [No Abstract]   [Full Text] [Related]  

  • 20. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF
    Stintzing S; Seufferlein T; Rosé C; Reichenbach F; Lüftner D
    Clin Colorectal Cancer; 2022 Sep; 21(3):244-251. PubMed ID: 35654691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.